Premium
Labetalol (AH5158), a Competitive Alpha‐and Beta‐Receptor Blocking Drug, in the Management of Hypertension
Author(s) -
Rosei E. Agabiti,
Brown J. J.,
Fraser R.,
Lever A. F.,
Morton J. J.,
Robertson J. I. S.,
Trust P. M.
Publication year - 1976
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1976.tb03341.x
Subject(s) - labetalol , medicine , propranolol , blood pressure , bradycardia , anesthesia , plasma renin activity , clonidine , pharmacology , renin–angiotensin system , heart rate
Summary: Labetalol (AH5158), a competitive alpha‐and beta‐receptor blocking drug, in the management of hypertension. E. A. Rosei, J. J. Brown, R. Fraser, A. F. Lever, J. J. Morton, J. I. S. Robertson and P. M. Trust, Aust. N.Z. J. Med. , 1976, 6 , pp. 83–88. The effects of intravenous labetalol, a drug with both alpha‐and beta‐adrenergic receptor blocking actions, have been studied in 20 severely hypertensive patients. There was a prompt and sustained fall in arterial pressure; severe hypotension did not occur in recumbent patients but postural hypotension was common. Pulse rate was consistently reduced, but bradycardia was not a problem. Significant and correlated falls in plasma angiotensin II and aldosterone were seen. In a direct comparison with intravenous propranolol, labetalol was less effective in lowering plasma angiotensin II, but more effective in reducing blood pressure. Oral labetalol provided good control of blood pressure and other features in two patients with phaeochromocytoma. Intravenous labetalol was similarly effective in controlling a hypertensive crisis following clonidine withdrawal.